RT Journal Article
SR Electronic
T1 Clusters of comorbidities in unclassifiable interstitial lung disease
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3744
DO 10.1183/13993003.congress-2021.PA3744
VO 58
IS suppl 65
A1 Thomas Skovhus Prior
A1 Charlotte Hyldgaard
A1 Sebastiano Emanuele Torrisi
A1 Sissel Kronborg-White
A1 Claudia Ganter
A1 Michael Kreuter
A1 Elisabeth Bendstrup
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3744.abstract
AB Introduction: The impact of comorbidities in patients with unclassifiable interstitial lung disease (uILD) is sparsely studied. We aimed to describe clusters of comorbidities in uILD and their prognosis.Methods: uILD patients from 2 ILD centers (Aarhus, Denmark; Heidelberg, Germany) were identified and 20 prespecified comorbidities were registered. Self-organizing maps were used to compute clusters of comorbidities. Kaplan-Meier survival estimates and the log-rank test was used for survival estimates.Results: In total, 249 uILD patients were identified (median age 70, 60% male, FVC 76%, DLCO 50%). Three clusters were observed in the Aarhus cohort (143 patients) and verified in the Heidelberg cohort (106 patients): Few comorbidities (FC), cardiovascular (CV) and emphysema (EM) (Figure 1). Patients in the FC cluster were younger, while patients in the CV cluster were older, former smokers, had cardiac and cerebrovascular disease, arterial hypertension, chronic renal failure, sleep apnea and thyroid disease. In the EM cluster, emphysema, pulmonary hypertension, osteoporosis, reflux disease and current smoking were prevalent. Two-year survival in the FC, CV and EM clusters was 82%, 74% and 73%, respectively, p = 0.41.Conclusion: Three distinct comorbidities clusters were identified in uILD patients. These clusters could represent phenotypes in uILD, but no mortality difference was observed, possibly due to a limited median follow-up time of 1.4 years.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3744.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).